Skip to Main Content
Contribute Try STAT+ Today

Rise and shine, everyone. Another busy day is on the way. We can tell because the hum of life is seen and heard outside our window — garbage trucks are rumbling by, dog walkers are promenading up and back, and car horns are blaring on nearby streets. As for us, we are engaged in our usual morning ritual of brewing cups of stimulation. Our choice today is the ever-seasonal pumpkin spice. Feel free to join us. Meanwhile, here are a few tidbits to help you cope on your own journey. We hope you have a smashing day and, as always, do keep in touch. …

The U.S. Securities and Exchange Commission is investigating claims Cassava Sciences (SAVA) manipulated research results of its experimental Alzheimer’s drug, The Wall Street Journal reports. Cassava disclosed in a securities filing it is cooperating with government investigations. The U.S. National Institutes of Health, which awarded $20 million in grants to Cassava and its academic collaborators since 2015 for drug development, is also examining the claims. The accusations appeared in a petition filed in August to the U.S. Food and Drug Administration asking it to suspend Cassava clinical trials. The petitioners are two doctors who doubt Cassava research and shorted its stock.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment